LDN for Migraine and Chronic Headache: What the Evidence Actually Shows
Migraine is not simply a bad headache. It is a neurological disease that can bring throbbing or disabling head pain, nausea, light and sound sensitivity, visual or sensory aura, fatigue, cognitive symptoms, and substantial disruption to work and daily life.
That burden helps explain why low-dose naltrexone, or LDN, has entered migraine conversations. LDN is discussed as a possible way to influence pain signaling and neuroimmune activity. Those ideas are scientifically interesting. They are not the same as proof that LDN prevents migraine, reliably stops an attack, or works as well as established migraine treatments.
The most accurate conclusion today is straightforward: direct migraine evidence exists, but it is preliminary, small, and insufficient to establish efficacy. LDN is not FDA-approved to treat or prevent migraine.
Considering LDN as part of a broader care plan? Explore Scripx low-dose naltrexone care or contact the Scripx team for an individualized medication review. A prescriber should review opioid exposure, headache pattern, current migraine therapies, and other conditions before LDN is considered.
First, Is It Migraine or Another Headache Disorder?
“Headache” covers many different diagnoses. Migraine, tension-type headache, cluster headache, new daily persistent headache, and headaches caused by another medical condition are not interchangeable.
The International Classification of Headache Disorders defines chronic migraine as headache on at least 15 days per month for more than three months, with migraine features on at least eight days per month. That definition matters because a person with chronic migraine may need a different treatment strategy than someone with occasional attacks.
A headache diary can help a clinician see patterns. Useful details include headache days, migraine-feature days, attack duration, suspected triggers, aura, nausea, medications taken, response to treatment, sleep, menstrual timing, and any recent medication changes.
Seek urgent medical evaluation for a sudden, explosive headache, a major change from an established pattern, new weakness or other neurological symptoms, fever or systemic illness, a headache following injury, or a concerning headache during pregnancy or postpartum. New headache later in life, or in someone with cancer or immune suppression, also deserves prompt assessment. A supplement or off-label medication trial should never delay evaluation of a red flag.
Why Is LDN Being Discussed for Migraine?
Naltrexone is an opioid antagonist approved at standard doses for alcohol dependence and opioid blockade. “Low-dose naltrexone” refers to smaller, off-label doses used in clinical practice for selected conditions. There is no single FDA-approved LDN product or migraine dosing standard.
Researchers have proposed that lower doses may affect microglia, Toll-like receptor 4 signaling, inflammatory mediators, endogenous opioid pathways, or central pain processing. Migraine biology also involves trigeminovascular signaling and calcitonin gene-related peptide, commonly called CGRP.
The overlap makes a hypothesis plausible enough to study. It does not show that LDN meaningfully changes migraine frequency, severity, aura, disability, or disease course in patients.
What Direct Migraine Research Has Reported
A small acute-treatment preprint
One randomized, double-blind, placebo-controlled study tested low-dose naltrexone, acetaminophen, and two naltrexone-acetaminophen combinations for a single moderate or severe migraine attack. Ninety-two participants were randomized and 72 completed the study.
In the report, the LDN-alone group included 19 participants and the placebo group included 17. The authors reported a higher two-hour pain-freedom response with LDN than placebo. However, the trial was small, completion was uneven across treatment groups, and the work was posted as a preprint rather than a peer-reviewed publication. It did not establish LDN as a reliable acute migraine treatment.
A 12-person prevention preprint
A second randomized study enrolled only 12 adults and compared an LDN-acetaminophen combination with placebo for episodic migraine prevention. Six participants were assigned to each group. The reported difference in monthly migraine days during the double-blind period did not reach statistical significance. An open-label extension included only five people.
This study cannot tell us whether LDN alone prevents migraine because the intervention also contained acetaminophen. Its extremely small sample, open-label extension, and preprint status sharply limit confidence in the findings.
A one-patient case report
A published case report described a patient with multiple sclerosis and chronic migraine who used LDN together with the Wahls Protocol, a substantial dietary intervention. The patient's migraine frequency and severity reportedly improved.
Case reports can generate research questions, but they cannot separate the effects of LDN from the dietary protocol, natural symptom fluctuation, expectancy, or other aspects of care. One patient's experience cannot establish what most patients should expect.
Registered research does not equal proven treatment
Additional LDN headache studies have been registered, including a small study involving chronic migraine with fibromyalgia and new daily persistent headache. A registered protocol shows that researchers intend to test an idea. It is not an efficacy result, and results should not be assumed before they are reported and evaluated.
Evidence Snapshot: Reported Versus Unproven
LDN Is Not a Substitute for Evidence-Based Migraine Care
Migraine treatment is usually divided into acute treatment, used during an attack, and preventive treatment, used to reduce future attack frequency or burden. The best plan depends on diagnosis, attack frequency, disability, nausea, aura, cardiovascular history, pregnancy potential, medication access, and prior response.
Established acute options may include selected nonprescription analgesics, triptans, gepants, ditans, anti-nausea therapy, and nonoral formulations when vomiting or rapid attack escalation makes tablets difficult to use. Preventive options may include medications from several classes, CGRP-targeting therapies, onabotulinumtoxinA for eligible chronic migraine, and neuromodulation devices.
The American Headache Society states that CGRP-targeting therapies should be considered a first-line approach for migraine prevention alongside previous first-line treatments, without requiring failure of other preventive classes first. That recommendation reflects a substantially larger evidence base than is available for LDN.
LDN might still be discussed as an individualized off-label option in selected circumstances. It should not be marketed or understood as equivalent to a proven migraine therapy.
Medication-Overuse Headache Changes the Treatment Plan
Frequent use of acute headache medicines can be associated with medication-overuse headache, or MOH. The ICHD-3 definition includes headache on at least 15 days per month in someone with a pre-existing headache disorder and regular overuse of acute or symptomatic medication for more than three months.
The day threshold depends on the medication class. For example, overuse criteria generally begin at 10 days per month for triptans, opioids, and combination analgesics, and 15 days per month for simple analgesics such as nonsteroidal anti-inflammatory drugs. These are diagnostic thresholds, not targets or personalized instructions.
If acute medication use is rising, simply adding another medication may miss the central problem. A clinician may need to review the diagnosis, introduce or optimize prevention, plan withdrawal when appropriate, and provide a safe rescue strategy. LDN has not been established as a treatment for MOH.
The Opioid Issue Is Not Optional
Naltrexone blocks opioid receptors. Official labeling contraindicates standard-dose naltrexone in people receiving opioid analgesics, those currently dependent on opioids, and those in acute opioid withdrawal. Starting naltrexone after recent opioid exposure can precipitate severe withdrawal. It can also interfere with opioid pain relief.
This matters even if a person does not think of themselves as an “opioid user.” The medication list should include prescription pain medicines, cough products, antidiarrheal medicines, buprenorphine, methadone, tramadol, and any intermittent or nonmedical opioid exposure. Upcoming surgery or dental work also matters because opioid analgesia may be considered.
Opioids themselves are generally poor routine migraine tools. The American Headache Society notes a high risk of medication-overuse headache, dependence, and migraine progression when opioids are used frequently.
Do not start, stop, or time LDN around an opioid on your own. A prescriber must determine whether LDN is appropriate and how any transition should be managed.
Can LDN Be Used With Triptans, Gepants, or CGRP Antibodies?
There is no universal answer based only on the word “migraine.” A medication review should consider the exact drug, formulation, dose, timing, liver and kidney function, pregnancy status, cardiovascular conditions, and other prescriptions.
LDN does not have the same direct opioid-receptor conflict with triptans, gepants, or CGRP monoclonal antibodies that it has with opioid agonists. That does not prove a combination is effective, necessary, or risk-free. The main clinical question is whether every medication has a clear role and whether the overall plan controls attacks without creating avoidable adverse effects or overuse.
For a broader review, see LDN drug interactions, opioids, GLP-1s, and more.
Where GLP-1 Medications Fit
Semaglutide and tirzepatide may be prescribed for approved metabolic indications. They are not FDA-approved migraine treatments. A person may appropriately receive migraine care and GLP-1 therapy at the same time, but the goals should remain separate.
The crossover matters because headache can occur during GLP-1 treatment. The current Wegovy prescribing information lists headache among common adverse reactions. GLP-1 therapy may also cause nausea, vomiting, diarrhea, reduced intake, and volume depletion. Dehydration, irregular meals, and disrupted sleep can all aggravate headache susceptibility in some people.
Semaglutide delays gastric emptying and may affect absorption of oral medications. This does not mean every oral migraine medicine will fail, but it makes timing, symptom tracking, and alternative routes worth discussing when nausea, vomiting, or inconsistent response is present.
If headaches begin or worsen after starting a GLP-1 medicine or increasing the dose, document timing rather than assuming the migraine disease itself is progressing. A clinician can review hydration, food intake, glucose-lowering therapies, blood pressure, adverse effects, and the need for a different titration or treatment plan.
There are no adequate controlled trials showing that an LDN-GLP-1 combination prevents migraine, stops attacks, improves aura, or produces extra weight loss. Any combined use should be based on separate indications and an individualized review.
Learn more about Scripx weight-management care.
What About Retatrutide and Migraine?
Retatrutide is investigational. As of August 2026, it has not been FDA-approved for any condition, and the FDA states that retatrutide cannot be used in compounding under federal law. It has not been established as a migraine treatment, alone or with LDN.
Products advertised online as “compounded retatrutide” should not be treated as an approved or validated shortcut. A migraine claim does not change the product's regulatory status or supply-chain risks.
What a Thoughtful LDN Evaluation Should Include
Before prescribing LDN for a person with migraine or frequent headache, a clinician should clarify:
-
The headache diagnosis. Migraine, chronic migraine, medication-overuse headache, cluster headache, new daily persistent headache, and secondary headache need different evaluation.
-
The evidence standard. The patient should understand that LDN use is off label and that current migraine evidence is preliminary.
-
All opioid exposure. This includes scheduled, occasional, procedural, and nonprescription sources.
-
Current acute-medication days. Frequency matters as much as the medication name.
-
Established options already tried. Lack of access, intolerance, contraindications, and inadequate response are different problems.
-
Other conditions and medications. Liver disease, kidney disease, pregnancy, mood symptoms, sleep disorders, cardiovascular risk, and metabolic therapy can change the plan.
-
A measurable trial plan. Track monthly migraine days, headache days, acute-medication days, intensity, disability, and adverse effects.
-
A stop or reassessment point. Continuing indefinitely without defined benefit makes it difficult to know whether treatment is helping.
When a low dose or customized dosage form is clinically necessary, a compounding pharmacy may prepare patient-specific medication under a valid prescription. Compounded drugs are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing. Quality, formulation, beyond-use dating, and patient counseling therefore matter.
Learn about Scripx compounding services.
The Bottom Line
LDN for migraine is a research question, not an established answer. Two small preprints and one case report provide enough signal to justify better studies, but not enough evidence to promise acute relief or prevention. The prevention preprint studied LDN with acetaminophen in only 12 people, and the case report combined LDN with a major dietary protocol.
People with frequent headaches also need evaluation for the correct diagnosis, medication overuse, secondary causes, and treatment options supported by stronger evidence. Opioid exposure is a critical safety issue because naltrexone can block opioid analgesia and precipitate withdrawal in an opioid-dependent person.
GLP-1 medications may be appropriate for separate metabolic goals, but they are not proven migraine treatments. Headache, gastrointestinal effects, dehydration, and delayed gastric emptying can complicate symptom interpretation and medication use.
Ready for an individualized review? Explore Scripx LDN care or contact Scripx. The goal is not to chase a trend. It is to build a medically coherent plan with clear outcomes, safety checks, and realistic expectations.
Medical disclaimer
This content is for education only and is not medical advice, diagnosis, or a prescription. LDN is an off-label use of naltrexone and is not FDA-approved for migraine. Do not start or stop naltrexone, opioids, migraine treatments, or GLP-1 therapy without guidance from a qualified clinician. Seek urgent care for a sudden severe headache, new neurological symptoms, or other concerning changes.
4. Frequently Asked Questions
Does low-dose naltrexone help migraines?
It is not established. Small preliminary studies and a case report have reported possible benefit, but the evidence is too limited to conclude that LDN reliably treats migraine.
Is LDN FDA-approved for migraine prevention?
No. LDN is an off-label use of naltrexone, and naltrexone is not FDA-approved to prevent or acutely treat migraine.
Can LDN stop a migraine attack?
A small randomized preprint tested LDN for a single attack and reported a higher response than placebo in a small subgroup. The study did not provide enough evidence to establish LDN as an acute migraine treatment.
Can I take LDN with a triptan or CGRP medication?
There is not the same direct opioid conflict, but combined use still requires a medication review. A clinician should check the exact drugs, health conditions, treatment goals, and whether each medicine has a clear role.
Can LDN be taken with opioid pain medication?
This can be dangerous or make opioid analgesia ineffective. Naltrexone blocks opioid receptors and can precipitate severe withdrawal in someone who is opioid-dependent. Do not combine or transition between them without prescriber direction.
Does LDN treat medication-overuse headache?
LDN has not been established as a treatment for medication-overuse headache. Management usually requires reviewing acute-medication frequency, improving prevention, and developing a clinician-guided withdrawal and rescue plan when appropriate.
Can semaglutide or tirzepatide cause headaches?
Headache can occur during GLP-1 therapy. Gastrointestinal effects, reduced intake, or dehydration may also contribute. New or worsening headaches should be reviewed in the context of timing, dose changes, hydration, nutrition, and other medications.
Does a GLP-1 medication treat migraine?
No GLP-1 medication is FDA-approved as a migraine treatment. Emerging scientific questions in specific headache conditions should not be generalized into a claim that GLP-1 therapy treats migraine.
Is LDN plus a GLP-1 proven for migraine or weight loss?
No. There are no adequate controlled trials establishing the combination for migraine prevention, acute relief, or enhanced weight loss. The medications may be prescribed for separate goals after individualized review.
Is retatrutide available for migraine treatment?
No. Retatrutide is investigational and is not FDA-approved for any condition as of August 2026. The FDA states that it cannot be used in compounding under federal law.